Hematology · Leukemia
The facts most likely to be tested
Press 1–5 to rate · ↑↓ to navigate
Chronic Lymphocytic Leukemia is the most common leukemia in adults in Western countries, typically presenting in asymptomatic elderly patients with isolated lymphocytosis.
Peripheral blood smears characteristically demonstrate smudge cells (or basket cells), which are fragile, disrupted lymphocytes resulting from the slide preparation process.
Flow cytometry is the diagnostic gold standard, revealing a clonal population of B-cells co-expressing CD5, CD19, and CD23, with characteristically dim/weak CD20 (distinguishing CLL from mantle cell lymphoma, which shows bright CD20 and is CD23-negative).
Patients frequently develop autoimmune hemolytic anemia (AIHA, ~5-10% of cases) or immune thrombocytopenia (ITP); the causative autoantibodies are typically produced by non-malignant, polyclonal bystander B-cells activated via T-helper-cell dysregulation triggered by the CLL clone, rather than secreted directly by the malignant clone itself.
Transformation to an aggressive high-grade lymphoma, known as Richter transformation, should be suspected in patients presenting with rapidly enlarging lymph nodes, fever, and weight loss.
Clinical staging is determined by the Rai staging system, which relies on the presence of lymphadenopathy, hepatosplenomegaly, anemia, and thrombocytopenia.
Asymptomatic patients with early-stage disease are managed with observation (watch and wait), as early treatment does not improve overall survival.
Vignette unlocked
A 72-year-old male presents for a routine physical examination and is found to have a white blood cell count of 45,000/µL. He reports no fevers, night sweats, or unintentional weight loss. Physical examination reveals bilateral cervical and axillary lymphadenopathy and a palpable spleen tip. Peripheral blood smear shows a predominance of mature-appearing lymphocytes and numerous smudge cells. Flow cytometry confirms the presence of CD5+ and CD23+ B-cells.
What is the most appropriate initial management for this patient?
Observation (watch and wait)
The patient has asymptomatic, early-stage CLL (Rai stage I/II); per the standard of care, asymptomatic patients do not require immediate chemotherapy and are monitored for disease progression.
Full handout
High yield triage
Etiology / Epidemiology
Most common leukemia in Western adults; median age of diagnosis is 70 years.
Clinical Manifestations
Often asymptomatic (incidental lymphocytosis); classic B-symptoms and lymphadenopathy.
Diagnosis
Flow cytometry showing clonal B-cells with CD5 and CD19 co-expression.
Treatment
Observation for asymptomatic disease; preferred first-line for symptomatic disease per NCCN v2.2026 is venetoclax+obinutuzumab or a next-generation BTK inhibitor (zanubrutinib or acalabrutinib); ibrutinib remains effective but is no longer preferred first-line due to higher cardiotoxicity.
Prognosis
Transformation to aggressive lymphoma known as Richter transformation.
Full handout
Epidemiology & Etiology
Predominantly affects the elderly with a male-to-female ratio of 2:1. It is a malignancy of mature B-lymphocytes that fail to undergo apoptosis. No clear ionizing-radiation association; herbicide/Agent Orange exposure is a recognized (VA presumptive, NAS-reviewed) risk association.
Pertinent Anatomy
Involves the bone marrow, peripheral blood, and lymphoid tissues. Splenomegaly and hepatomegaly occur due to massive infiltration of malignant lymphocytes.
Pathophysiology
Characterized by the accumulation of incompetent, monoclonal B-cells in the G0 phase of the cell cycle. These cells express CD5, CD19, CD20, and CD23. Impaired humoral immunity leads to hypogammaglobulinemia and increased infection risk.
Clinical Manifestations
Most patients are diagnosed via routine CBC showing isolated lymphocytosis. Physical exam reveals painless lymphadenopathy and splenomegaly. B-symptoms (fever, night sweats, weight loss) indicate advanced disease. Autoimmune hemolytic anemia (AIHA) is a common paraneoplastic complication.
Diagnosis
The gold standard is flow cytometry of peripheral blood, showing clonal B-cells co-expressing CD5, CD19, and CD23 with characteristically dim CD20. Peripheral smear classically shows smudge cells (fragile lymphocytes). Diagnostic threshold requires a sustained absolute clonal B-lymphocyte count ≥ 5,000/µL for at least 3 months.
Treatment
Asymptomatic patients are managed with observation. Symptomatic patients meeting iwCLL active-disease criteria (e.g., cytopenias, bulky/symptomatic nodes) receive targeted therapy: NCCN v2.2026 preferred first-line options are venetoclax + obinutuzumab (fixed-duration) or a next-generation BTK inhibitor (zanubrutinib or acalabrutinib +/- obinutuzumab); ibrutinib remains effective but is no longer preferred first-line due to higher rates of atrial fibrillation (ELEVATE-RR, ALPINE trials). Avoid chemotherapy in patients with significant comorbidities. Monitor for tumor lysis syndrome specifically during venetoclax initiation (5-week dose ramp-up).
Prognosis
Disease progression is monitored via the Rai staging system. Patients are at high risk for recurrent infections due to hypogammaglobulinemia. Watch for Richter transformation, transformation to an aggressive high-grade lymphoma — most commonly (~90-95%) diffuse large B-cell lymphoma, with a minority transforming to Hodgkin lymphoma.
Differential Diagnosis
Hairy Cell Leukemia: pancytopenia; flow cytometry positive for CD103, CD11c, CD25, CD123, and Annexin A1 (TRAP stain is a legacy test, largely superseded)
Follicular Lymphoma: Nodal architecture effacement on biopsy
Mantle Cell Lymphoma: Cyclin D1 overexpression
Viral Lymphocytosis: Transient, usually EBV or CMV
Acute Lymphoblastic Leukemia: Blasts on smear and rapid onset